• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » U.K. court bars Edwards TMVR sales, gives Abbott win in patent spat

U.K. court bars Edwards TMVR sales, gives Abbott win in patent spat

March 12, 2020 By Nancy Crotti

gavel, legalA judge in the England issued an injunction yesterday barring Edwards Lifesciences from selling its Pascal transcatheter mitral valve repair (TMVR) device in the U.K.

A different judge had previously denied Abbott’s petition for such an injunction. Yesterday, Judge Colin Birss of the High Court of England and Wales also ruled that two patents held by Abbott unit Evalve for its MitraClip TMVR device were valid and that Edwards’ Pascal device infringed them.

The decisions came after two separate trials, at which Edwards had argued that Abbott’s MitraClip patents were invalid, and that barring Pascal sales in the U.K. would go against public interest.

Edwards contended that Pascal was “significantly different” from MitraClip and other TMVR devices and thus could be used in patients who were unsuited to treatment with those devices. The company also argued that physicians who prefer Pascal to MitraClip should have access to it, and that Pascal should be available for patients in whom MitraClip implantation was unsuccessful. Abbott agreed to and Birss ordered a “carve-out” of the injunction allowing for Pascal to be used in those patients.

Birss decided that giving doctors the choice was not enough to deny Abbott’s petition for an injunction.

“It is manifest that there is a wealth of data underpinning the use of MitraClip, by contrast there is much less data on Pascal,” Birss wrote. “I find that overall there is, at least yet, no hard clinical data from which to infer any objectively superior performance by Pascal over MitraClip in any circumstances in any patients.”

Edwards said it respectfully disagrees with Birss’ decision.

“Edwards continues to strongly believe that its differentiated Pascal technology does not infringe the patents invoked by Abbott and intends to appeal,” a company spokeswoman said in an email to MassDevice. “Edwards is not updating its financial guidance.”

Currently, TMVR procedures are not covered by the UK’s National Health Service, resulting in a very small number of such procedures in the country, according to court documents.  However, NHS England is expected to begin paying for the procedure, according to a report by Law360.

Filed Under: Business/Financial News, Catheters, Featured, Legal News, Patent Infringement, Replacement Heart Valves, Structural Heart, Wall Street Beat Tagged With: Abbott, Edwards Lifesciences, Evalve

More recent news

  • Breaking: Sequel to launch twiist automated insulin delivery system next month
  • Dexcom shares U.S. report on CGM benefits for type 2 diabetes
  • Data backs Medtronic MiniMed 780G for type 2, children as company seeks expanded indications
  • Endogenex data supports type 2 diabetes procedure
  • Ambu wins FDA clearance for first single-use cysto-nephroscope

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy